Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Andrew G. Polson(Sunesis (United States)), Allen Ebens(Unknown), Mary J. Cole(Angiogenesis Foundation), Shang‐Fan Yu(Genesys (United States)), Dan Eaton(Enzo Life Sciences (United States)), Gladys S. Ingle, Suzanna Clark, Bing Zheng, Lynne Giere, Alvin Gogineni(Angiogenesis Foundation), Kristi Elkins, Jean-Philippe Stéphan, Sarajane Ross, Wesley Chang(California Institute of Technology), Suzie J. Scales(Unknown), Judy Young, Changchun Du, Jo-Anne Hongo, Dionysos Slaga, Christine Tan, Richard Vandlen(PDL BioPharma (United States))
Cited by 172
Related Papers
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
|Nature Immunology|2008|1.5k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
|Cancer Cell|2014|1.1k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997